Post by Nadica (She/Her) on Jun 16, 2024 9:16:06 GMT
The Effect of COVID-19 on Cardiovascular Diseases and the Need for Beta-Blocker Dose Modification - Published June 12, 2024
Less a treatment study and more a study of those who require special treatment after covid
Highlights from Dr. Harry Spoelstra:
- Patients with preexisting CVD should be closely monitored during and after recovery from SARS-CoV-2 infection due to the higher risk of complications and the potential need for modifications in the treatment of chronic diseases.
- Patients with coronary artery diseases especially may need an increase in beta-blocker doses after recovery( MEDICATION adjustment!)
- This is an important issue for future research, especially in the context of long COVID-19
Abstract
Introduction and purpose: The Coronavirus Disease 2019 (COVID-19) and its effects on patients remain the main focus of many researchers across the world. One of the challenges faced by medical professionals is the impact of the infection on the course of chronic diseases. Manifestations of the infection are observed mainly in the respiratory system, but other organs, particularly the cardiovascular system, are also frequently affected. Recent data indicates that arterial hypertension and cardiovascular diseases (CVD) are the most prevalent comorbidities in patients suffering from SARS-CoV-2 infection.
Material and methods: This study aimed to investigate the impact of SARS-CoV-2 infection on the cardiovascular system. Apart from the literature review we conducted a retrospective study to check the necessity for modification of chronic treatment in patients with CVD after recovery from COVID-19, particularly regarding the use of beta blockers.
Results: Using the Mann-Whitney U test a positive correlation (p = 0.04) was found between the presence of coronary artery disease before COVID-19 and a need for an increase in the beta-blockers dose.
Conclusions: Patients with preexisting CVD should be closely monitored during and after recovery from SARS-CoV-2 infection due to the higher risk of complications and the potential need for modifications in the treatment of chronic diseases. Patients with coronary artery diseases may need an increase in beta-blocker doses after recovery. This is an important issue for future research, especially in the context of long COVID-19.
Keywords
beta-blockers, SARS-Cov- 2, cardiovascular diseases, Long-COVID
Less a treatment study and more a study of those who require special treatment after covid
Highlights from Dr. Harry Spoelstra:
- Patients with preexisting CVD should be closely monitored during and after recovery from SARS-CoV-2 infection due to the higher risk of complications and the potential need for modifications in the treatment of chronic diseases.
- Patients with coronary artery diseases especially may need an increase in beta-blocker doses after recovery( MEDICATION adjustment!)
- This is an important issue for future research, especially in the context of long COVID-19
Abstract
Introduction and purpose: The Coronavirus Disease 2019 (COVID-19) and its effects on patients remain the main focus of many researchers across the world. One of the challenges faced by medical professionals is the impact of the infection on the course of chronic diseases. Manifestations of the infection are observed mainly in the respiratory system, but other organs, particularly the cardiovascular system, are also frequently affected. Recent data indicates that arterial hypertension and cardiovascular diseases (CVD) are the most prevalent comorbidities in patients suffering from SARS-CoV-2 infection.
Material and methods: This study aimed to investigate the impact of SARS-CoV-2 infection on the cardiovascular system. Apart from the literature review we conducted a retrospective study to check the necessity for modification of chronic treatment in patients with CVD after recovery from COVID-19, particularly regarding the use of beta blockers.
Results: Using the Mann-Whitney U test a positive correlation (p = 0.04) was found between the presence of coronary artery disease before COVID-19 and a need for an increase in the beta-blockers dose.
Conclusions: Patients with preexisting CVD should be closely monitored during and after recovery from SARS-CoV-2 infection due to the higher risk of complications and the potential need for modifications in the treatment of chronic diseases. Patients with coronary artery diseases may need an increase in beta-blocker doses after recovery. This is an important issue for future research, especially in the context of long COVID-19.
Keywords
beta-blockers, SARS-Cov- 2, cardiovascular diseases, Long-COVID